1. Itakura K, Hirose T, Crea R, Riggs AD, Heyneker HL, Bolivar F, et al. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science. 1977; 198(4321):1056-63. [
DOI:10.1126/science.412251] [
PMID]
2. Zhang ZX, Nong FT, Wang YZ, Yan CX, Gu Y, Song P, et al. Strategies for efficient production of recombinant proteins in Escherichia coli: alleviating the host burden and enhancing protein activity. Microb Cell Fact. 2022; 21(1):191. [
DOI:10.1186/s12934-022-01917-y] [
PMID] [
PMCID]
3. Menon RK, Trucco M, Majzoub JA, Stratakis CA. Molecular endocrinology, endocrine genetics, and precision medicine. In: Sperling MA, editor. Sperling pediatric endocrinology. 5th ed. Philadelphia: Elsevier; 2021. p. 9-29. [
DOI:10.1016/B978-0-323-62520-3.00002-6]
4. Puetz J, Wurm FM. Recombinant proteins for industrial versus pharmaceutical purposes: a review of process and pricing. Processes. 2019; 7(8):476. [
DOI:10.3390/pr7080476]
5. Zhang J, Du C, Pan Y, Zhang Z, Feng R, Ma M, et al. Optimization of a novel expression system for recombinant protein production in CHO cells. Sci Rep. 2024; 14(1):24913. [
DOI:10.1038/s41598-024-76995-6] [
PMID] [
PMCID]
6. Jain T, Suntharalingam P, Cooney JM, Davidowitz RA. Mammalian cell culture in biopharmaceutical manufacturing: a historical perspective. Biotechnol Prog. 2022; 38(6):e3302.
7. Puente-Massaguer E, Gòdia F. Recombinant protein production in suspension mammalian cells using the BacMam baculovirus expression system. Methods Mol Biol. 2024; 2829:329-39. [
DOI:10.1007/978-1-0716-3961-0_25] [
PMID]
8. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014; 5:172. [
DOI:10.3389/fmicb.2014.00172]
9. Neef J, van Dijl JM, Buist G. Recombinant protein secretion by Bacillus subtilis and Lactococcus lactis: pathways, applications, and innovation potential. Essays Biochem. 2021; 65(2):187-95. [
DOI:10.1042/EBC20200171] [
PMID] [
PMCID]
10. Kim H, Yoo SJ, Kang HA. Yeast synthetic biology for the production of recombinant therapeutic proteins. FEMS Yeast Res. 2015; 15(1):1-16. [
DOI:10.1111/1567-1364.12195] [
PMID]
11. De Brabander P, Uitterhaegen E, Delmulle T, De Winter K, Soetaert W. Challenges and progress towards industrial recombinant protein production in yeasts: a review. Biotechnol Adv. 2023; 64:108121. [
DOI:10.1016/j.biotechadv.2023.108121] [
PMID] [
PMCID]
12. Vieira Gomes AM, Souza Carmo T, Silva Carvalho L, Mendonça Bahia F, Parachin NS. Comparison of yeasts as hosts for recombinant protein production. Microorganisms. 2018; 6(2):41. [
DOI:10.3390/microorganisms6020038] [
PMID] [
PMCID]
13. Tang H, Wang S, Wang J, Song M, Xu M, Zhang M, et al. N-hypermannose glycosylation disruption enhances recombinant protein production by regulating secretory pathway and cell wall integrity in Saccharomyces cerevisiae. Sci Rep. 2016; 6:25654. [
DOI:10.1038/srep25654] [
PMID] [
PMCID]
14. Hamilton SR, Gerngross TU. The glycosylation potential of yeast: using yeast species to produce human glycoproteins. Appl Microbiol Biotechnol. 2007; 74(4):735-50.
15. Gerngross TU, Smith KA. Posttranslational modifications in Saccharomyces cerevisiae and Pichia pastoris. Methods Enzymol. 2003; 373:154-74.
16. Huang M, Wang G, Qin J, Petranovic D, Nielsen J. Engineering the protein secretory pathway of Saccharomyces cerevisiae enables improved protein production. Proc Natl Acad Sci U S A. 2018; 115(47):E11025-32. [
DOI:10.1073/pnas.1809921115] [
PMID] [
PMCID]
17. Sharp PM, Cowe E. Synonymous codon usage in Saccharomyces cerevisiae. Yeast. 1991; 7(8):657-76. [
DOI:10.1002/yea.320070702] [
PMID]
18. Pan Y, Yang J, Wu J, Yang L, Fang H. Current advances of Pichia pastoris as cell factories for production of recombinant proteins. Front Microbiol. 2022; 13:1059777. [
DOI:10.3389/fmicb.2022.1059777] [
PMID] [
PMCID]
19. Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol. 2004; 22(11):1428-37. [
DOI:10.1038/nbt1028] [
PMID]
20. Zahrl RJ, Peña DA, Mattanovich D, Gasser B. Systems biotechnology for protein production in Pichia pastoris. FEMS Yeast Res. 2017; 17(7):fox097. [
DOI:10.1093/femsyr/fox068] [
PMID]
21. Tripathi NK, Shrivastava A. Recent developments in bioprocessing of recombinant proteins: expression hosts and process development. Front Bioeng Biotechnol. 2019; 7:420. [
DOI:10.3389/fbioe.2019.00420] [
PMID] [
PMCID]
22. Nevalainen H, Peterson R. Making recombinant proteins in filamentous fungi-are we expecting too much? Front Microbiol. 2014; 5:75.
23. Liu D, Garrigues S, de Vries RP. Heterologous protein production in filamentous fungi. Appl Microbiol Biotechnol. 2023; 107(16):5019-33. [
DOI:10.1007/s00253-023-12660-8] [
PMID] [
PMCID]
24. Yee CM, Zak AJ, Hill BD, Wen F. The coming age of insect cells for manufacturing and development of protein therapeutics. Ind Eng Chem Res. 2018; 57(31):10061-70. [
DOI:10.1021/acs.iecr.8b00985] [
PMID] [
PMCID]
25. Jarvis DL, Jarvis JA. Baculovirus expression vectors: a retrospective and prospectus. Protein Expr Purif. 2017; 125:1-12.
26. Yadav M, Sarkar S, Kumar A. Diversifying expression platforms for biopharmaceuticals and industrial enzymes. In: Verma P, editor. Industrial microbiology and biotechnology: a new horizon of the microbial world. 1st ed. Singapore: Springer Nature Singapore; 2024. p. 573-603. [
DOI:10.1007/978-981-97-6270-5_19] [
PMID] [
PMCID]
27. Yagi H, Yanaka S, Yogo R, Ikeda A, Onitsuka M, Yamazaki T, et al. Silkworm pupae function as efficient producers of recombinant glycoproteins with stable-isotope labeling. Biomolecules. 2020; 10(11):1482. [
DOI:10.3390/biom10111482] [
PMID] [
PMCID]
28. Xu H. The advances and perspectives of recombinant protein production in the silk gland of silkworm Bombyx mori. Transgenic Res. 2014; 23(5):697-706. [
DOI:10.1007/s11248-014-9826-8] [
PMID]
29. Shepelev MV, Kalinichenko SV, Deykin AV, Korobko IV. Production of recombinant proteins in the milk of transgenic animals: current state and prospects. Acta Naturae. 2018; 10(3):40-7. [
DOI:10.32607/20758251-2018-10-3-40-47] [
PMID] [
PMCID]
30. Maksimenko OG, Deykin AV, Khodarovich YM, Georgiev PG. Use of transgenic animals in biotechnology: prospects and problems. Acta Naturae. 2013; 5(1):33-46. [
DOI:10.32607/20758251-2013-5-1-33-46] [
PMID] [
PMCID]
31. Feng Z, Li X, Fan B, Zhu C, Chen Z. Maximizing the production of recombinant proteins in plants: from transcription to protein stability. Int J Mol Sci. 2022; 23(21):13516. [
DOI:10.3390/ijms232113516] [
PMID] [
PMCID]
32. Warzecha H, Mason S, Stöger E. Recombinant protein expression in plants for medical applications. Curr Opin Biotechnol. 2023; 84:102977.
33. Strasser R, Gomord V. Potential of plant-based systems for recombinant protein production. Essays Biochem. 2021; 65(2):241-53.
34. Moon KB, Park JS, Park YI, Song IJ, Lee HJ, Cho HS, et al. Development of systems for the production of plant-derived biopharmaceuticals. Plants (Basel). 2020; 9(1):30. [
DOI:10.3390/plants9010030] [
PMID] [
PMCID]
35. Capell T, Christou P. Progress in plant molecular farming. Curr Opin Biotechnol. 2004; 15(2):172-6. [
DOI:10.1016/j.copbio.2004.01.009] [
PMID]
36. Mark JKK, Lim CSY, Nordin F, Tye GJ. Expression of mammalian proteins for diagnostics and therapeutics: a review. Mol Biol Rep. 2022; 49(11):10593-608. [
DOI:10.1007/s11033-022-07651-3] [
PMID] [
PMCID]
37. Griffiths AD. Mammalian cell culture: fundamentals and applications. 2nd ed. Berlin: Springer; 2000.
38. Khan KH. Gene expression in mammalian cells and its applications. Adv Pharm Bull. 2013; 3(2):257-63.
39. Bari AU. Chronology of cutaneous leishmaniasis: an overview of the history of the disease. J Pak Assoc Dermatol. 2017; 27(1):24-27. [
DOI:10.66344/jpad.v16i1.842]
40. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res. 2017; 6:750. [
DOI:10.12688/f1000research.11120.1] [
PMID] [
PMCID]
41. Raymond F, Boisvert S, Roy G, Ritt JF, Légaré D, Isnard A, et al. Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res. 2012; 40(3):1131-47. [
DOI:10.1093/nar/gkr834] [
PMID]
42. Mendoza-Roldan JA, Votypka J, Bandi C, Epis S, Modry D, Ticha L, et al. Leishmania tarentolae: a new frontier in the epidemiology and control of the leishmaniases. Transbound Emerg Dis. 2022; 69(5):e1326-37. [
DOI:10.1111/tbed.14660] [
PMCID]
43. Basile G, Peticca M. Recombinant protein expression in Leishmania tarentolae. Mol Biotechnol. 2009; 43(3):273-8. [
DOI:10.1007/s12033-009-9213-5] [
PMID]
44. Senra RL, Pereira HS, Schittino LMP, Fontes PP, de Oliveira TA, Ribon AOB, et al. Co-expression of human sialyltransferase improves N-glycosylation in Leishmania tarentolae and optimizes the production of humanized therapeutic glycoprotein IFN-β. J Biotechnol. 2024; 394:24-33. [
DOI:10.1016/j.jbiotec.2024.08.002] [
PMID]
45. Chia S, Tay SJ, Song Z, Yang Y, Walsh I, Pang KT. Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content. Biomed Pharmacother. 2023; 163:114757. [
DOI:10.1016/j.biopha.2023.114757] [
PMID]
46. Abdi Ghavidel A, Jajarmi V, Bandehpour M, Kazemi B. Polycistronic expression of multi-subunit complexes in the eukaryotic environment: a narrative review. Iran J Parasitol. 2022; 17(3):286-95. [
DOI:10.18502/ijpa.v17i3.10618] [
PMID] [
PMCID]
47. Jones JD. Leishmania tarentolae: an alternative approach to the production of monoclonal antibodies to treat emerging viral infections. Infect Dis Poverty. 2015; 4:8. [
DOI:10.1186/2049-9957-4-8] [
PMID] [
PMCID]
48. Zimna M, Krol E. Leishmania tarentolae as a platform for the production of vaccines against viral pathogens. NPJ Vaccines. 2024; 9 (1): 212. [
DOI:10.1038/s41541-024-01005-9] [
PMID] [
PMCID]
49. Medina AC, Acevedo Ospina H, Descoteaux A. Immunomodulatory properties of Leishmania tarentolae extracellular vesicles containing the spike protein of SARS-CoV-2. Front Parasitol. 2024; 3:1306478. [
DOI:10.3389/fpara.2024.1306478] [
PMID] [
PMCID]
50. Blum B, Bakalara N, Simpson L. A model for RNA editing in kinetoplastid mitochondria: "guide" RNA molecules transcribed from maxicircle DNA provide the edited information. Cell. 1990; 60(2):189-98. [
DOI:10.1016/0092-8674(90)90735-W] [
PMID]
51. White TC, Fase-Fowler F, van Luenen H, Calafat J, Borst P. The h circles of Leishmania tarentolae are a unique amplifiable system of oligomeric DNAs associated with drug resistance. J Biol Chem. 1988; 263(32):16977-83. [
DOI:10.1016/S0021-9258(18)37486-6] [
PMID]
52. LeBowitz JH, Coburn CM, McMahon-Pratt D, Beverley SM. Development of a stable Leishmania expression vector and application to the study of parasite surface antigen genes. Proc Natl Acad Sci U S A. 1990; 87(24):9736-40. [
DOI:10.1073/pnas.87.24.9736] [
PMID] [
PMCID]
53. Johnston WA, Alexandrov K. Production of eukaryotic cell-free lysate from Leishmania tarentolae. Methods Mol Biol. 2014; 1118:1-15. [
DOI:10.1007/978-1-62703-782-2_1] [
PMID]
54. Alfaro-Palma J, Johnston WA, Behrendorff J, Cui Z, Varasteh Moradi S, Alexandrov K. Development of lyophilized eukaryotic cell-free protein expression system based on Leishmania tarentolae. ACS Synth Biol. 2024; 13(2):449-56. [
DOI:10.1021/acssynbio.3c00428] [
PMID]
55. Breitling R, Klingner S, Callewaert N, Pietrucha R, Geyer A, Ehrlich G, et al. Non-pathogenic trypanosomatid protozoa as a platform for the production of eukaryotic proteins. Protein Expr Purif. 2002; 25(2):209-18. [
DOI:10.1016/S1046-5928(02)00001-3] [
PMID]
56. Kazemi B, Tahvildar-Bideroni GH, Hashemi Feshareki SR, Javadian E. Isolation of a lizard Leishmania promastigote from its natural host in Iran. J Biol Sci. 2004; 4:620-3. [
DOI:10.3923/jbs.2004.620.623]
57. Ehya F, Kalantari S, Bandehpour M, Kazemi B. Preliminary information of Iranian Lizard Leishmania promastigote transcriptome sequencing by next-generation sequencing (NGS) method. Iran J Parasitol. 2023; 18(3):362-8. [
DOI:10.18502/ijpa.v18i3.13759] [
PMID] [
PMCID]
58. Hieronimus K, Donauer T, Klein J, Hinkel B, Spänle JV, Probst A, et al. A modular cloning toolkit for the production of recombinant proteins in Leishmania tarentolae. Microb Cell. 2024; 11:128-42. [
DOI:10.15698/mic2024.04.821] [
PMID] [
PMCID]
59. Abdi Ghavidel A, Bandehpour M, Noori E, Jajarmi V, Kazemi B. Comparing the yield of recombinant human factor VII protein expressed by the rDNA-promoter with the CMV-promoter in Iranian Lizard Leishmania. Iran J Parasitol. 2024; 19(2):192-202. [
DOI:10.18502/ijpa.v19i2.15855] [
PMID] [
PMCID]
60. Klatt S, Simpson L, Maslov DA, Konthur Z. Leishmania tarentolae: taxonomic classification and its application as a promising biotechnological expression host. PLoS Negl Trop Dis. 2019; 13(7):e0007424. [
DOI:10.1371/journal.pntd.0007424] [
PMID] [
PMCID]
61. Abdi Ghavidel A, Aghamiri S, Raee P, Mohammadi-Yeganeh S, Noori E, Bandehpour M, et al. Recent advances in CRISPR/Cas9-mediated genome editing in Leishmania strains. Acta Parasitol. 2024; 69:121-34. [
DOI:10.1007/s11686-023-00756-0] [
PMID]
62. Kushnir S, Gase K, Breitling R, Alexandrov K. Development of an inducible high-yield protein expression system for Leishmania tarentolae. Protein Expr Purif. 2005; 42(1):37-46. [
DOI:10.1016/j.pep.2005.03.004] [
PMID]
63. Cattaneo GM, Varotto-Boccazzi I, Molteni R, Ronchetti F, Gabrieli P, Mendoza-Roldan JA, et al. A novel chemically defined medium for the biotechnological and biomedical exploitation of the cell factory Leishmania tarentolae. Sci Rep. 2024; 14(1):9562. [
DOI:10.1038/s41598-024-60383-1] [
PMID] [
PMCID]
64. de Oliveira Filho VA, Garcia MSA, Rosa LB, Giorgio S, Miguel DC. An overview of Leishmania in vitro cultivation and implications for antileishmanial screenings against promastigotes. Parasitologia. 2024; 4(4):305-18. [
DOI:10.3390/parasitologia4040027]
65. Abdi Ghavidel A, Aghamiri S, Jajarmi V, Bandehpour M, Kazemi B. The influence of different culture media on the growth and recombinant protein production of Iranian Lizard Leishmania promastigote. Iran J Parasitol. 2022; 17(4):543-53. [
DOI:10.18502/ijpa.v17i4.11282] [
PMID] [
PMCID]
66. Choi J, Keum KC, Lee SY. Engineering of Escherichia coli for enhanced production of recombinant proteins. Biotechnol Adv. 2006; 24(5):480-90.
67. Lv W, Cai M. Advancing recombinant protein expression in Komagataella phaffii: opportunities and challenges. FEMS Yeast Res. 2025; 25:foaf010.
68. Li ZM, Fan ZL, Wang XY, Wang TY. Factors affecting the expression of recombinant protein and improvement strategies in Chinese hamster ovary cells. Front Bioeng Biotechnol. 2022; 10:880155. [
DOI:10.3389/fbioe.2022.880155] [
PMID] [
PMCID]
69. Hamdi A, Széliová D, Ruckerbauer DE, Rocha I, Borth N, Zanghellini J. Key challenges in designing CHO chassis platforms. Processes. 2020; 8:643. [
DOI:10.3390/pr8060643]
70. de Oliveira TA, Silva WD, da Rocha Torres N, Badaró de Moraes JV, Senra RL, de Oliveira Mendes TA, et al. Application of the Lexsy Leishmania tarentolae system as a recombinant protein expression platform: a review. Process Biochem. 2019; 87:164-73. [
DOI:10.1016/j.procbio.2019.08.019]
71. Jalali A, Bandehpour M, Chegeni R, Ghanbarian H, Mardani-Dashti Y, Zarkesh-Esfahani SH, et al. Expression, purification, and evaluation of anti-IL-2Rα antibody secreted by Leishmania tarentolae. Int J Pept Res Ther. 2021; 27(1):301-7. [
DOI:10.1007/s10989-020-10088-6]
72. Mirzaahmadi S, Asaadi-Tehrani G, Bandehpour M, Davoudi N, Tahmasbi L, Hosseinzadeh N, et al. Expression of recombinant human coagulation factor VII by the lizard Leishmania expression system. J Biomed Biotechnol. 2011; 2011:873874. [
DOI:10.1155/2011/873874] [
PMID] [
PMCID]
73. Masroori N, Halabian R, Mohammadipour M, Roushandeh AM, Rouhbakhsh M, Najafabadi AJ, et al. High-level expression of functional recombinant human coagulation factor VII in insect cells. Biotechnol Lett. 2010; 32(6):803-9. [
DOI:10.1007/s10529-010-0227-7] [
PMID]
74. Berkner KL, Busby S, Davie E, Hart C, Insley M, Kisiel W, et al. Expression of high levels of functional human vitamin K-dependent protein in mammalian cells: factor VII. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 1:531-41. [
DOI:10.1101/SQB.1986.051.01.065] [
PMID]
75. Wajih N, Owen J, Wallin R. Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection. Thromb Res. 2008; 122(3):405-10. [
DOI:10.1016/j.thromres.2007.11.002] [
PMID] [
PMCID]
76. Donyavi T, Bandehpour M, Kazemi B. Preparation of transgenic Iranian Lizard Leishmania coding HIL-12. Iran J Microbiol. 2017; 9(5):305-11.
77. Donyavi T, Chegeni R, Bandehpour M, Mohammadi-Yeganeh S, Zahedi-Zavaram H, Kazemi B, et al. Evaluation of transgenic Iranian lizard Leishmania encoding human IL-12 as a candidate vaccine against experimental cutaneous leishmaniasis in susceptible BALB/c mice. J Med Microbiol Infect Dis. 2026; 14(2):115-23.
78. Taromchi AH, Kazemi B, Mahmazi S, Bandehpour M. Heterologous expression of human IL-29 (IFN-λ1) in Iranian Lizard Leishmania. Iran J Biotechnol. 2013; 11(3):168-74. [
DOI:10.5812/ijb.12468]
79. Yadegari Z, Bandehpour M, Kazemi B, Sharifi-Sarasiabi K. Expression of recombinant human Amelogenin in Iranian Lizard Leishmania and its biological function assay. Iran J Public Health. 2015; 44(7):987-96.